Company Overview
About Delineate
Delineate is a United States-based AI clinical trial design and biomedical data extraction company — providing pharmaceutical companies, academic research teams, and contract research organizations (CROs) with AI-powered systematic review automation that accelerates the data extraction and evidence synthesis workflows critical for designing better, faster clinical trials in the $10 billion clinical trial design and data services market. Partnered with two top-10 global pharmaceutical companies, Delineate has performed some of the largest systematic-review studies ever conducted in drug development, delivering 15x more processed studies than industry standard timelines and reducing certain study completion times from months to weeks through AI models that extract and analyze data from biopharma research papers, patents, and regulatory documents at scale.
Business Model & Competitive Advantage
Delineate's AI data extraction platform combines custom large language models with computer vision models trained specifically for biomedical literature: the clinical trial design process requires synthesizing evidence from hundreds to thousands of existing clinical studies to understand what treatment arms, dosing regimens, patient populations, and endpoints have already been tested — a systematic review process that traditionally requires teams of PhD-level researchers spending months manually extracting data tables, adverse event rates, efficacy outcomes, and patient criteria from papers. Critically, much of this data is "trapped" in figures and plots (bar charts of efficacy results, Kaplan-Meier survival curves, dose-response graphs) rather than in machine-readable tables — Delineate's computer vision models extract quantitative data from these visual formats with the accuracy required for clinical evidence synthesis. The rigorous quality control processes (automated consistency checks, uncertain extraction flagging for human review) address the clinical-grade accuracy requirements that pharmaceutical companies apply to evidence used for regulatory submissions.
Competitive Landscape 2025–2026
In 2025, Delineate competes in the AI clinical trial design, systematic review automation, and biopharma data extraction market with Sciome (computational toxicology and systematic review, NIH-contracted), Elsevier's Reaxys (scientific data extraction, RELX group), and Scite (AI citation analysis for scientific literature, $7M raised) for pharmaceutical company clinical evidence synthesis and trial design support. The systematic review and meta-analysis market has been one of the highest-value AI application areas in pharmaceutical R&D — the evidence synthesis step that informs trial design decisions (what comparator to use, what endpoint is most sensitive, what dose range to test) has historically been the most labor-intensive and time-consuming pre-clinical research activity. Top-10 pharma partnerships validate Delineate's clinical-grade accuracy for the high-stakes drug development workflows where errors in evidence synthesis could lead to suboptimal trial designs and significant capital waste. The 2025 strategy focuses on expanding the pharmaceutical company partnerships for late-phase trial design support, building the regulatory evidence package automation for NDA and BLA submissions, and growing the platform into real-world evidence (RWE) data extraction from electronic health records.
Recent Activity
View all →How always-on tracking reduces repeat work and supports better decisions Research budgets are rarely wasted in one obvious place. They don’t usually […]
From one-off projects to embedded insight partnerships Businesses have become more always-on than the research models built to support them. […]
Synthetic data is not hard to generate. It is hard to know when to trust. Insights teams are being asked […]
Material Event filed 2026-06-12
Synthetic data is not hard to generate. It is hard to know when to trust. AI can now create modelled […]
Delineate has announced a series of senior leadership appointments and promotions as part of its continued investment in client partnerships, […]
Last week, Delineate was part of an important conversation about the future of research, as MRS brought together leaders from […]
“Prompt engineering” has had a funny glow-up. A couple of years ago, it sounded like something you needed a hoodie […]
“Prompt engineering” has had a funny glow-up. A couple of years ago, it sounded like something you needed a hoodie […]
Material Event filed 2026-05-06
Quarterly Report filed 2026-05-06
IIEX North America felt like a useful reflection of where the insights industry is now. Not where it was a […]
Company Timeline
Major milestones in Delineate's journey
Leadership Team
Meet the leaders behind Delineate
Emily Nieves
Jawad Iqbal
Key Differentiators
Emerging Innovator
Delineate is an emerging player bringing innovative solutions to the Healthcare Tech market.
Frequently Asked Questions
Estimated Visibility Trend (Beta)
Simulated 8-week rolling score
Based on estimated brand signals. Historical tracking coming soon.
Similar Brands
Browser Use
Browser Use is an open-source project that provides a Python library allowing AI agents and large language models to control web browsers as a tool. The library sits between LLM APIs and browser autom
Idexx Laboratories
IDEXX Laboratories is the global leader in veterinary diagnostics and information technology for companion animal healthcare, founded in 1983 by David Shaw in Westbrook, Maine, where it remains headqu
Revvity
Revvity, Inc. (formerly PerkinElmer) is a global life science tools and diagnostics company, rebranded in 2023 to signal its transformation from a diversified instruments company into a focused provid
GE HealthCare
GE HealthCare Technologies Inc. is a Chicago, Illinois-based medical technology and digital health company — publicly traded on the NASDAQ (NASDAQ: GEHC) as an S&P 500 Health Care component — designin
Incyte
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation,
Biogen
Biogen Inc. is a Cambridge, Massachusetts-based neuroscience biopharmaceutical company — publicly traded on NASDAQ (NASDAQ: BIIB) as an S&P 500 Health Care component — researching, developing, and com
Compare Delineate with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Delineate? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Delineate Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Delineate vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →